Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 16th February, 2023 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding approval of the requests received for issue of Duplicate Share Certificate(s) and issue of letter of confirmation in lieu of the physical share certificate to the registered shareholder(s) and/or their legal heir(s) in accordance with the provisions of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022.
16-02-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Injectable Facility (F-3) At Karkhadi

 This is to inform the exchange that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our Injectable Facility (F-3) at Karkhadi from 18th August, 2022 to 30th August, 2022. This was a pre-approval inspection for ANDAs filed with the USFDA. The Company has already started receiving ANDA approvals manufactured at this facility. We request you to kindly take the same on record.
16-02-2023

Alembic Pharma lowers US sales guidance from $500 mn to $300 mn for next 3-4 years

 Around 29 per cent of the total business of the Vadodara-based drug maker comes from the US sales which manufactures and markets generic drugs which are reverse-engineered, cheap versions of branded patented drugs
08-02-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 With reference to the captioned matter, please find enclosed herewith the transcript of the Conference Call held on 1st February, 2023. We request you to kindly take the same on record.
07-02-2023

Neutral Alembic Pharma; target of Rs 580: Motilal Oswal

 Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 580 in its research report dated February 01, 2023.
03-02-2023

Alembic Pharma Q3 net dips 29% to Rs 122 cr, revenue rises to Rs 1,509 cr

 Alembic Pharmaceuticals on Thursday said its consolidated net profit declined by 29 per cent to Rs 122 crore in the December quarter. The Vadodara-based drug maker had reported a net profit of Rs 172 crore in the October-December quarter of last fiscal. Revenue from operations rose to Rs 1,509 crore in the period under review from Rs 1,272 crore in the year-ago period, Alembic Pharmaceuticals said in a statement. "The company witnessed top-line growth across all the verticals. In particular, the API business outperformed with a 65 per cent growth during the quarter," Alembic Pharmaceuticals Managing Director Pranav Amin stated.
02-02-2023

Alembic Pharma Consolidated December 2022 Net Sales at Rs 1,509.02 crore, up 18.66% Y-o-Y

 NULL
01-02-2023

Alembic Pharmaceuticals Results Earnings Call for Q3FY23

 Conference Call with Alembic Pharmaceuticals Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
01-02-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 With reference to the captioned matter, this is to inform the exchange that the audio recording has been hosted on the website of the Company and can be accessed at https://alembicpharmaceuticals.com/quarterly-results/ We request you to kindly take the same on record.
01-02-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Appointment of Company Secretary and Compliance Officer

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), this is to inform the exchange that: 1. Mr. Charandeep Singh Saluja (ICSI Membership No. A28061) has resigned from the position of the Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company w.e.f. 21st March, 2023 (after the closure of business hours). 2. Ms. Manisha Saraf (ICSI Membership No. A20998) is appointed as the Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company w.e.f. 1st April, 2023. The details as required under Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015, are given in Annexure - A, to this letter.
01-02-2023
Next Page
Close

Let's Open Free Demat Account